TB-500 — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction TB-500 is a synthetic peptide derived from thymosin β-4, the predominant member of the β-thymosin family found in human plasma, platelets, and many cell types. The commercial "TB-500" reagent is typically a fragment corresponding to the active region of thymosin β-4 rather than the full 43-amino-acid native protein. Investigational; not FDA-approved. ## Mechanism of Action Thymosin β-4 sequesters monomeric G-actin and regulates actin cytoskeletal dynamics. Functionally, TB-500 promotes cell migration, angiogenesis (new blood-vessel formation), upregulates growth-factor signaling, and accelerates tissue repair across muscle, tendon, ligament, skin, and corneal tissue in research models. ## Research Indications Research contexts: acute musculoskeletal injury (tendinopathy, ligament strain, muscle tear), chronic soft-tissue pain, post-surgical recovery, corneal-injury models, and adjunctive cardiac-injury research. Frequently paired with BPC-157 in recovery-focused protocols. ## Reconstitution Typical 5 mg lyophilized vial: add **2.5 mL of bacteriostatic water**, swirl gently. Final concentration **2000 mcg/mL (2 mg/mL)** — each 0.1 mL (10 units on a U-100 insulin syringe) delivers 200 mcg. ## Dosing Protocol (research literature) Research protocols typically use a **loading phase**: **2–5 mg subcutaneously twice weekly for 4–6 weeks**, then a **maintenance phase**: **2 mg SC once every 2 weeks** as needed. Local-injection protocols near the affected tissue use smaller doses (0.5–2 mg per site) at the same cadence. ## Administration Subcutaneous into abdominal fat for systemic protocols, or near the affected tissue for local recovery protocols. Rotate sites. ## Storage & Handling Lyophilized: refrigerate (2–8°C); freeze (–20°C) for long-term storage. Reconstituted: refrigerate; stable approximately **30 days**. Protect from light. ## Side Effects Generally well-tolerated in available reports: mild injection-site reactions, occasional transient fatigue or head-fog in the first few days of loading. Long-term safety data are limited. ## Contraindications Pregnancy, lactation, active malignancy (theoretical concern given pro-angiogenic activity), acute infection. ## Monitoring Baseline functional and pain instrument appropriate to the affected tissue. Re-measure at 4 and 8 weeks. Imaging follow-up where the indication and resources warrant. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.